Article Information
History
- October 21, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Catherine S. Storm1,
- Demis A. Kia1,
- Mona Almramhi1,2,
- Dilan Athauda1,
- International Parkinson’s Disease Genomics Consortium (IPDGC)+,
- Stephen Burgess3,4,
- Thomas Foltynie1 and
- Nicholas W. Wood1,*
- 1Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, United Kingdom
- 2Department of Medical Laboratory Technology, King Abdulaziz University, Jeddah, Saudi Arabia
- 3MRC Biostatistics Unit, University of Cambridge, United Kingdom
- 4Cardiovascular Epidemiology Unit, University of Cambridge, United Kingdom
- ↵*email: n.wood{at}ucl.ac.uk
Posted October 21, 2020.
Predicting the efficacy of exenatide in Parkinson’s disease using genetics – a Mendelian randomization study
